相关实验视频
Updated: Jul 2, 2026

09:17
Using Retinal Imaging to Study Dementia
Published on: November 6, 2017
22.2K
早期检测轻度认知障碍,使用基于眼部生物标志物的风险评分名录
Mohammed Seid Hussen1, Bess Yin-Hung Lam2, Wei Gao3,4
1Laboratory of Experimental Optometry (Neuroscience), School of Optometry, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, China.
Frontiers in aging neuroscience
|December 19, 2025
概括
一种新的诺莫图谱工具使用视网膜和视觉生物标志物用于早期检测老年人轻度认知障碍 (MCI). 这种评分系统显示出高精度和临床实用性,用于机会性查.
科学领域:
- 眼科和神经科学 眼科和神经科学
- 生物标志物和诊断工具
- 老龄化和认知健康问题
背景情况:
- 全球日益老龄化导致认知障碍患病率上升.
- 早期,亚临床的视网膜结构和血管变化与认知能力下降相关.
- 关于这些视网膜生物标志物对认知变化的预测性能的证据有限.
研究的目的:
- 开发和验证基于名录的评分工具,用于轻度认知障碍 (MCI) 的机会性查.
- 为早期MCI检测整合非侵入性视网膜和视觉生物标志物.
主要方法:
- 有望招募60岁以上的参与者.
- 通过光学连贯断层扫描和血管学进行视网膜成像.
- 后勤回归建模来预测MCI,其次是nomogram开发和验证 (bootstrapping,ROC分析,决策曲线分析).
主要成果:
- 中部斑点厚度,外鼻斑点 perfusion 密度和对比度灵敏度与MCI独立相关.
- 诺米图实现了0.90 (AUC0.87) 的辨别力,精度为86%,灵敏度为85%,特异性为87%.
- 决策曲线分析表明显著的临床净益.
结论:
- 一个集网膜和视觉生物标志物的动态,基于名录的评分工具被开发和验证用于早期MCI检测.
- 该工具显示出高的分辨能力和临床实用性.
- 对认知衰退的预后价值进行进一步的研究是有必要的.
相关概念视频
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

